MEDICUS PHARMA LTD. Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals
MEDICUS PHARMA LTD. (MDCX) had Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals of $766.43 thousand as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals · last filed 2026-03-25
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $766.43K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $994.65K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $170.60K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals |
|---|---|
| 2025-12-31 | $766.43K 10-K · filed 2026-03-25 |
| 2024-12-31 | $994.65K 10-K · filed 2026-03-25 |
| 2023-12-31 | $170.60K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |